Breeze Holdings Acquisition Corp. (BRZH) to Combine with YD Biopharma in $694M Deal

Breeze Holdings Acquisition Corp. (OTC:BRZH) has entered into a definitive agreement to combine with drug developer YD Biopharma at an enterprise value of $694 million. Taipei-based YD is developing a trio of treatment candidates meant to treat some eye conditions and screen for pancreatic and breast cancer, whose patents it has under license. The combined
Read More